Skip to content
Equity Capital Market
  • Privacy Policy
  • Start Here
  • Research
    • LPTH case study
    • PLUG case study
    • STDN case study
  • IPO & Public Offerings
  • Economy & Macro
  • Latest
  • Stock Market
  • Market Education
  • Energy & Commodities
  • Capital Markets
  • Federal Reserve & Rates
  • About
  • Contact

merck earnings

Merck Raises 2026 Guidance After Q1 Revenue Beat, Despite $9B Deal Charge

September 12, 2026May 1, 2026 by Bruno M.
Merck Raises 2026 Guidance After Q1 Revenue Beat, Despite $9B Deal Charge

Merck Q1 2026: $16.3B revenue beat, guidance raised. A $9B acquisition charge drove a GAAP loss, but Winrevair growth signals strong underlying fundamentals.

Categories Stock Market Tags drug stocks Q1 2026, keytruda, merck earnings, MRK stock, pharmaceutical stocks, stock market

Explore ECMSource

New here? Begin with our guide to the site, then explore the subjects that match what you want to understand.

  • Start Here
  • Market Education
  • Stock Market
  • Capital Markets
  • Federal Reserve & Rates

Recent Posts

  • American Express Posts Record $20.1B Q3 Revenue, Raises 2026 Guidance
  • Rights Offerings Explained: Subscription Ratios and TERP Math
  • CRH Closes $8.5B Arcosa Acquisition: Cash, Debt, Delisting
  • Why Humana and UnitedHealth Are Dropping 1M Medicare Members
  • Price Return vs. Total Return: How Reinvestment Shapes Wealth

Subscribe to Our Newsletter

Oh hi there 👋
It’s nice to meet you.

Sign up to receive awesome content in your inbox, every month.

We don’t spam! Read our privacy policy for more info.

Check your inbox or spam folder to confirm your subscription.

  • Privacy Policy
  • Editorial Policy
  • Corrections Policy
  • Financial Disclaimer
  • Contact
  • About Bruno M.
  • Investor Tools
© 2026 Equity Capital Market • Built with GeneratePress